Philadelphia Business Journal - "Industry and Academic Partners to Target Inflammatory Bowel Disease"

 – June 27, 2013  –– 

Janssen Biotech Inc. and Johnson & Johnson Innovation have established a research alliance with the Icahn School of Medicine at Mount Sinai to advance the scientific understanding of, and develop the next generation of treatments for, inflammatory bowel disease, which affects an estimated 1.4 million Americans.  The industry and academic partnership is designed to bring together Janssen's research and development capabilities with an early-stage life science investment through the Johnson & Johnson Innovation center in Boston and Mount Sinai's expertise in computational biology, and clinical and translational research in inflammatory bowel disease. Learn more